ライフサイエンスコーパス: xenotransplantation

1 when pig cells are transplanted into humans (xenotransplantation).

2 LA class I is a target for genome editing in xenotransplantation.

3 play a pathophysiologic role in pig-to-human xenotransplantation.

4 ot form tumors following human-to-nude mouse xenotransplantation.

5 e requirement for immunosuppression in islet xenotransplantation.

6 a promising avenue for future approaches to xenotransplantation.

7 und using pig-to-primate heterotopic cardiac xenotransplantation.

8 cute rejection (HAR) in Gal-positive cardiac xenotransplantation.

9 rigenicity and differentiation potential via xenotransplantation.

10 ve marrow niche environment of scid mice for xenotransplantation.

11 barrier to the clinical application of islet xenotransplantation.

12 ted to aid the clinical translation of islet xenotransplantation.

13 resent a new carbohydrate moiety involved in xenotransplantation.

14 EC membrane antigens detected after cardiac xenotransplantation.

15 fer insight into new therapies for allo- and xenotransplantation.

16 A were detected in baboons following porcine xenotransplantation.

17 may be activated with immunosuppression for xenotransplantation.

18 human anti-pig cellular response is key for xenotransplantation.

19 source of transplantable organs via modified xenotransplantation.

20 y response is of significance for success in xenotransplantation.

21 nt step toward the clinical applicability of xenotransplantation.

22 ERV) is considered one of the major risks in xenotransplantation.

23 b) present major obstacles in pig-to-primate xenotransplantation.

24 hyperacute organ rejection in pig to primate xenotransplantation.

25 d in the development of animals suitable for xenotransplantation.

26 by human complement, a model of pig-to-human xenotransplantation.

27 nt manner in a rat-to-mouse model of corneal xenotransplantation.

28 oundary that will need to be overcome within xenotransplantation.

29 stroma in the grafts for 2 months following xenotransplantation.

30 relevant, discordant, pig-to-baboon model of xenotransplantation.

31 actose (Gal) in pigs has proved a barrier to xenotransplantation.

32 but not PLHV-1, is activated in solid-organ xenotransplantation.

33 effective erythropoiesis 3 to 4 months after xenotransplantation.

34 y to be essential to the success of clinical xenotransplantation.

35 jor barrier to clinical application of organ xenotransplantation.

36 es a major immunologic barrier to successful xenotransplantation.

37 , would be one group that might benefit from xenotransplantation.

38 demonstrated after pig-to-baboon solid-organ xenotransplantation.

39 experimental protocol of pig-to-baboon heart xenotransplantation.

40 an ex vivo pre-clinical mouse model based on xenotransplantation.

41 d may further enhance the safety of clinical xenotransplantation.

42 ological, scientific, and ethical nuances of xenotransplantation.

43 may not constitute a direct major barrier to xenotransplantation.

44 ing acute allograft rejection and unknown in xenotransplantation.

45 PERV may pose an infectious risk in clinical xenotransplantation.

46 regarded as the major barrier to successful xenotransplantation.

47 nment of PERV infection of human cells after xenotransplantation.

48 but has not been observed in pig-to-primate xenotransplantation.

49 ipient and frequently become activated after xenotransplantation.

50 Antipig antibodies are a barrier to clinical xenotransplantation.

51 cells, raising concerns regarding safety of xenotransplantation.

52 ment of the retroviral risks of pig to human xenotransplantation.

53 to coagulopathies observed in pig-to-primate xenotransplantation.

54 clinically relevant pig-to-primate model of xenotransplantation.

55 suggesting avoidance of sensitization after xenotransplantation.

56 ctions has been documented in pig-to-primate xenotransplantation.

57 ls to address the safety concern in clinical xenotransplantation.

58 n observed frequently in pig-to-baboon renal xenotransplantation.

59 ing of pigs, and the unique problems of lung xenotransplantation.

60 to prolong graft survival in pig-to-primate xenotransplantation.

61 pig cells is a major obstacle to successful xenotransplantation.

62 causing hyperacute rejection in pig-to-human xenotransplantation.

63 ficant role in DIC associated with pulmonary xenotransplantation.

64 sistance when transgenic organs are used for xenotransplantation.

65 causing hyperacute rejection in pig-to-human xenotransplantation.

66 r what roles CTL will play in pig-into-human xenotransplantation.

67 topenia associated with pig-to-human hepatic xenotransplantation.

68 tolerance via mixed chimerism to facilitate xenotransplantation.

69 agulopathy has been proposed as a barrier to xenotransplantation.

70 ulopathy observed with renal and bone marrow xenotransplantation.

71 , acute and chronic allograft rejection, and xenotransplantation.

72 s is the critical step toward the success of xenotransplantation.

73 mmunological hurdle to successful discordant xenotransplantation.

74 the risk of in vivo infection of PERV after xenotransplantation.

75 ome the humoral immune barrier that prevents xenotransplantation.

76 uggesting that contamination occurred during xenotransplantation.

77 at may be applicable to clinical solid organ xenotransplantation.

78 cytosis of platelets in pig-to-primate liver xenotransplantation.

79 associated with vascularized pig-to-primate xenotransplantation.

80 es represents a major obstacle to successful xenotransplantation.

81 for clinical application of porcine-to-human xenotransplantation.

82 nd they may represent a source of organs for xenotransplantation.

83 allow for successful clinical application of xenotransplantation.

84 One possible solution to this problem is xenotransplantation.

85 terest in the immunotherapy of cancer and in xenotransplantation.

86 ammation and for improving graft survival in xenotransplantation.

87 itiation in anti-CD122-primed NOD/SCID mouse xenotransplantation.

88 C+/CD49e+ fraction produced tumors following xenotransplantation.

89 l progenitors remained highly malignant upon xenotransplantation.

90 ght have implications for clinical trials of xenotransplantation.

91 stained at higher levels than controls after xenotransplantation.

92 tes classic pathway complement activation in xenotransplantation.

93 renewal, nor enhanced in vivo engraftment in xenotransplantations.

94 d open new avenues of intervention to making xenotransplantation a clinical reality.

95 anoproteomics, stromal coculture, and BC LSC xenotransplantation analyses.

96 and culture of human tissue, bioengineering, xenotransplantation and genome editing, Induced pluripot

97 ity, to human AMR in allotransplantation and xenotransplantation and illustrates the current mechanis

98 unity to xenoantigens was only induced after xenotransplantation and not by immunization with porcine

99 f porcine endogenous retrovirus (PERV) after xenotransplantation and on the long-term immune response

100 ding the continuing debates on the ethics of xenotransplantation and the safeguards that should be im

101 Policies surrounding xenotransplantation, and many other emerging high-techno

102 This gene is responsible for generating xenotransplantation antigens resulting in hyperacute rej

103 This humanized ossicle xenotransplantation approach provides a system for model

104 In this study, using a xenotransplantation approach, we have modeled human pedi

105 NOD/LtSz-scid IL2Rgamma null(c) (NSG) mouse xenotransplantation approaches to elucidate leukemia-ini

106 work suggests that immunological barriers to xenotransplantation are not insurmountable.

107 or producing antigens that impose limits on xenotransplantation as they are discovered.

108 Here we show that modified xenotransplantation assay conditions, including the use

109 ith overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasivene

110 rmed the clinical relevance of the surrogate xenotransplantation assay for quantifying cells with rap

111 e combined immune-deficient (NOD/SCID) mouse xenotransplantation assay is the most commonly used surr

112 Modifications to xenotransplantation assays can therefore dramatically in

113 Furthermore, xenotransplantation assays demonstrated that a subset of

114 to drive the development of histiocytosis in xenotransplantation assays in vivo.

115 melanoma initiation in serial human-to-mouse xenotransplantation assays may be contained both among s

116 Xenotransplantation assays revealed that HSC activity is

117 specimens using in vitro culture and in vivo xenotransplantation assays shows that the combination of

118 However, refinements of xenotransplantation assays, alternative methods of quant

119 argeted leukemic stem cells in secondary AML xenotransplantation assays.

120 -forming progenitors, and LSCs as defined by xenotransplantation assays.

121 tem cell pool, as measured in 6- to 12-month xenotransplantation assays.

122 f rare subpopulations of engrafting cells in xenotransplantation assays.

123 esponse pathway and impaired tumor growth in xenotransplantation assays.

124 ype and enhanced tumor initiating ability in xenotransplantation assays.

125 se human cells to physiologically engraft in xenotransplantation assays.

126 of the Ethics Committee of the International Xenotransplantation Association is presented.

127 of the Ethics Committee of the International Xenotransplantation Association, Sykes et al. diagram im

128 Using a robust model of xenotransplantation based on NOD/SCID/IL2Rgammac-deficie

129 nce is likely to be essential for successful xenotransplantation because immune responses across xeno

130 Xenotransplantation, because of the complexity of the me

131 ogical obstacles are to be negotiated before xenotransplantation becomes a clinical reality.

132 of this important specificity, which limits xenotransplantation by causing hyperacute and delayed xe

133 Before xenotransplantation can be introduced successfully into

134 iated inhibition of tumor growth in a murine xenotransplantation cancer model.

135 Xenotransplantation carries numerous ethical dilemmas.

136 d into primates, bringing clinical trials of xenotransplantation closer.

137 Although DIC in renal or bone marrow xenotransplantation develops over a period of days, DIC

138 -linked galactose such as the immunodominant xenotransplantation epitope Galalpha1-3Galbeta1-4GlcNAc

139 atic removal of the immunodominant alpha3Gal xenotransplantation epitope.

140 nce barriers, implying a need for caution in xenotransplantation, especially of porcine tissues.

141 In vivo, xenotransplantation experiments demonstrated that the ho

142 Such xenotransplantation experiments in the NOD/SCID/MPSVII m

143 Xenotransplantation experiments using MPeMSCs demonstrat

144 In serial human-to-mouse xenotransplantation experiments, ABCB5+ melanoma cells p

145 studied extensively by investigators in the xenotransplantation field.

146 The potential of xenotransplantation for clinical application will requir

147 ould lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, there

148 Heterotopic cardiac xenotransplantation from alpha1,3-galactosyltransferase

149 f these observations, the safety of clinical xenotransplantation from miniature swine will be most en

150 Xenotransplantation from pigs could provide a potential

151 that composite thymokidney and thymic-tissue xenotransplantation from swine to baboons can induce don

152 To evaluate the safety of xenotransplantation further, we assessed the effect of c

153 Porcine islet xenotransplantation has been demonstrated in many animal

154 Xenotransplantation has been suggested as a potential so

155 on, the initial immune barrier to successful xenotransplantation, has been overcome with pig donors t

156 The immunological barriers to xenotransplantation have been, and remain, formidable.

157 has reduced the antibody-mediated barrier to xenotransplantation; herein, we describe the effect that

158 Balanced against the potential benefits of xenotransplantation, however, is the risk of human infec

159 other pig tissues to levels that enable the xenotransplantation humoral barrier to be overcome.

160 to overcome this limitation is by human cell xenotransplantation in immune-deficient mice.

161 Xenotransplantation in mesentery of pig pancreatic primo

162 When the results of pig organ xenotransplantation in nonhuman primates suggest a reali

163 ion, we tested the feasibility of hepatocyte xenotransplantation in nonhuman primates.

164 A profound thrombocytopenia limits hepatic xenotransplantation in the pig-to-primate model.

165 of sensitized transplant recipients and for xenotransplantation in which B-cell reactivity is a pred

166 Applications such as xenotransplantation, increased livestock productivity, b

167 n cord blood (hCB) CD34(+) cells followed by xenotransplantation into immunocompromised NSG mice or N

168 taining GFP-positive oocytes 1-2 weeks after xenotransplantation into immunodeficient female mice.

169 rigenic potential of human cancer cells is a xenotransplantation into immunodeficient mice.

170 ssing human male CCA cell line (EGI-1) after xenotransplantation into severe-combined-immunodeficient

171 Xenotransplantation is a promising strategy to alleviate

172 Although islet xenotransplantation is a promising therapy for type 1 di

173 Xenotransplantation is an attractive alternative to allo

174 cine cytomegalovirus (PCMV) in pig-to-baboon xenotransplantation is associated with xenograft injury

175 ts are subject to hyperacute rejection after xenotransplantation is contentious.

176 estion of patient and societal acceptance of xenotransplantation is discussed.

177 Xenotransplantation is frequently used to study normal a

178 sing interest in the use of swine organs for xenotransplantation lend importance to the question of w

179 lation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors.

180 Clinical trials of xenotransplantation may be influenced by various factors

181 In summary, the success of pig-to-primate xenotransplantation may necessitate immune tolerance to

182 Thus, the DIC in pulmonary xenotransplantation may represent a unique and/or accele

183 Successful xenotransplantation may require the development of novel

184 coagulation dysregulation in pig-to-primate xenotransplantation, may have additional benefits by neu

185 e retransplants and suggests that hepatocyte xenotransplantation might be useful as a bridge to liver

186 nviable human cardiomyocytes in this chronic xenotransplantation model (n>12; P=0.41).

187 Here we show that a xenotransplantation model bearing subcutaneous humanized

188 f-renew and to generate non-LICs in vivo The xenotransplantation model captures functional properties

189 ovide the first example of a patient-derived xenotransplantation model for a human histiocytic neopla

190 rate robust HBV and HCV infection in a novel xenotransplantation model in which large numbers of immu

191 y eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML.

192 We developed a novel mouse xenotransplantation model of retinal neovascularization

193 fic NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate consider

194 cells, as assessed in vivo through a murine xenotransplantation model, indicated that undifferentiat

195 In a xenotransplantation model, Mfn-2 gene therapy or Drp-1 i

196 In a KS mouse xenotransplantation model, ritonavir inhibited tumor for

197 I surface expression in vitro and in a mouse xenotransplantation model.

198 their successful application as donors in a xenotransplantation model.

199 AML cell lines and primary AML in an in vivo xenotransplantation model.

200 long-term tumorigenesis in a NOD/SCID serial xenotransplantation model.

201 ssed ability to form germ cells in vivo in a xenotransplantation model.

202 and inhibits tumor formation in a mouse AML xenotransplantation model.

203 r growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumo

204 -associated diseases in vivo, human-to-mouse xenotransplantation models for human blood and blood-for

205 drug resistance and impaired tumor growth in xenotransplantation models in vivo.

206 onstitutes short-term human hematopoiesis in xenotransplantation models is usually the dominant clone

207 However, conventional mouse xenotransplantation models lack essential human-specific

208 Finally, using two xenotransplantation models of imatinib-sensitive and ima

209 Xenotransplantation models recapitulated the correspondi

210 Xenotransplantation models represent powerful tools for

211 vitro and in vivo that can be used in human xenotransplantation models to examine cancer drug target

212 of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selec

213 mannose-binding lectin (MBL) in pig-to-human xenotransplantation models.

214 reduced tumor burden in vitro and in murine xenotransplantation models.

215 promised by the frailty of the current mouse xenotransplantation models.

216 ave demonstrated efficacy against AML LSC in xenotransplantation models.

217 ture and in vivo subcutaneous and orthotopic xenotransplantation models.

218 of PERV in vivo has been suggested in murine xenotransplantation models.

219 lls, is nontoxic to the cultured cells and a xenotransplantation mouse model under the conditions stu

220 d the tumorigenic potential of NB cells in a xenotransplantation mouse model.

221 Using a xenotransplantation murine model, we showed that Vgamma9

222 hallenges and other barriers associated with xenotransplantation need to be overcome.

223 not reduce the efficiency of medulloblastoma xenotransplantation nor did systemic therapy impact tumo

224 Xenotransplantation of acute myeloid leukemia (AML) into

225 Xenotransplantation of CD34(+) cells (n = 8 patients) or

226 This is the first demonstration that xenotransplantation of characterized OECs into the prima

227 tained in culture and in tumors arising from xenotransplantation of cultured cells in mice.

228 ion envisions growing new organs in situ via xenotransplantation of developing primordia from animal

229 Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 res

230 Xenotransplantation of genetically engineered porcine ch

231 Xenotransplantation of genetically modified pig organs o

232 Xenotransplantation of hepatocytes should be explored as

233 Xenotransplantation of human CTC clusters into zebrafish

234 Xenotransplantation of human eutopic endometrial tissue

235 e avatar mouse systems, which involve direct xenotransplantation of human tumor specimens into immuno

236 Although xenotransplantation of immunodeficient mice with human h

237 monstrated by either omental or subcutaneous xenotransplantation of liver scaffold cubes (5 x 5 x 5 m

238 Furthermore, TBI-based xenotransplantation of non-t(4;11) pre-B ALL enabled det

239 Xenotransplantation of porcine islets may be a strategy

240 might be the first patients to benefit from xenotransplantation of porcine organs.

241 Xenotransplantation of porcine tissues has the potential

242 Xenotransplantation of SCID/Beige mice with U87 cells an

243 Xenotransplantation of SF3B1 mutant HSCs leads to persis

244 Primary and secondary xenotransplantation of TAL1-rearranged leukemia allowed

245 Xenotransplantation of tumor-derived mural-like cells (G

246 Xenotransplantation offers a solution to the shortage of

247 transmission to human patients by pig tissue xenotransplantation or to study the potential pathogenes

248 owever, thrombocytopenia is also observed in xenotransplantation or xenoperfusion of other porcine or

249 r studies model protection in pig-to-primate xenotransplantation, our findings of IL-4 induction of A

250 anti-Gal antibodies as the major barrier to xenotransplantation, potentially bringing this modality

251 d to PERV in clinical use of certain porcine xenotransplantation products.

252 ransmission of PERV to recipients of porcine xenotransplantation products.

253 raised concern in the development of porcine xenotransplantation products.

254 portant implications for developing relevant xenotransplantation protocols.

255 ented the successful development of clinical xenotransplantation protocols.

256 this study shows that cellular barcoding and xenotransplantation providea useful model to study the b

257 yltransferase gene-knockout pig artery patch xenotransplantation, recipient baboons received no immun

258 A major focus of xenotransplantation research is the interaction between

259 al cells (PAEC) in two pig-to-human in vitro xenotransplantation settings.

260 ic islet transplantation and organ and islet xenotransplantation should be further explored.

261 c/severe combined immunodeficient (NOD/SCID) xenotransplantation strain.

262 becular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice.

263 lines and primary AML cells in vitro and in xenotransplantation studies in mice.

264 Orthotopic xenotransplantation studies revealed that control TICs f

265 We couple patient samples and xenotransplantation studies with this tractable in vitro

266 ells in vivo and for human leukemia cells in xenotransplantation studies.

267 This finding has broad implications for xenotransplantation, suggesting that porcine macrophages

268 rom umbilical cord blood (CB) as well as the xenotransplantation system that allows stable engraftmen

269 Over the past decade xenotransplantation systems have been used with increasi

270 Despite the challenges facing xenotransplantation, the extreme need for donor organs a

271 ed immunologic and physiological barriers to xenotransplantation, the limitations of the current anim

272 Xenotransplantation-the transplantation of organs betwee

273 Here, we used xenotransplantation to assess the tumorigenic potential

274 For xenotransplantation to become a clinical reality, we nee

275 ma cells in an unbiased way following serial xenotransplantation to define their individual fate beha

276 s hyperacute rejection of these organs after xenotransplantation to nonhuman primates.

277 ntly impede the translation of porcine islet xenotransplantation to sustained insulin independence cl

278 at will be necessary to minimize the risk of xenotransplantation to the recipients, their families, a

279 pigs, the most suitable donors for clinical xenotransplantation, to induce graft-versus-host disease

280 s (PERV) is a potential pathogen in clinical xenotransplantation; transmission of PERV in vivo has be

281 ed insulin response assay, and in vivo after xenotransplantation under the kidney capsule of streptoz

282 horts, and could therefore be candidates for xenotransplantation using GalT-KO swine donors.

283 nt limitation to the clinical application of xenotransplantation using pig organs is a rejection proc

284 Xenotransplantation using pigs as the source species for

285 Cardiac xenotransplantation was performed with GTKO (group 1; n=

286 strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of os

287 rehensive policies governing the practice of xenotransplantation, well-informed public opinions need

288 ype, as primary tumors that formed following xenotransplantation were larger, grew faster and develop

289 afts after pig-to-baboon heterotopic cardiac xenotransplantation when the induced anti-Gal antibody r

290 ly, lends encouragement that the barriers to xenotransplantation will eventually be overcome.

291 Successful xenotransplantation will likely depend, in part, on the

292 Rag2(-/-)gammac(-/-) mice as recipients for xenotransplantation with human immune systems (humanizat

293 Xenotransplantation with pig organs offers a medium-term

294 ibody before undergoing orthotopic pulmonary xenotransplantation with porcine lungs expressing human

295 Ten baboons underwent xenotransplantation with transgenic pig organs.

296 ve brought dramatic progress in the field of xenotransplantation, with the development of transgenic

297 urvived and morphologically integrated after xenotransplantation without immunosuppression.

298 , prolonging survival of mice that underwent xenotransplantation without inducing hematologic toxicit

299 ropriate for clinical application of cardiac xenotransplantation would be approached.

300 Xenotransplantation (XTx) provides a potential solution